DK2723347T3 - Forebyggelse og behandling af inflammationstilstande - Google Patents
Forebyggelse og behandling af inflammationstilstande Download PDFInfo
- Publication number
- DK2723347T3 DK2723347T3 DK12803312T DK12803312T DK2723347T3 DK 2723347 T3 DK2723347 T3 DK 2723347T3 DK 12803312 T DK12803312 T DK 12803312T DK 12803312 T DK12803312 T DK 12803312T DK 2723347 T3 DK2723347 T3 DK 2723347T3
- Authority
- DK
- Denmark
- Prior art keywords
- prevention
- treatment
- inflammatory conditions
- inflammatory
- conditions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/07—Retinol compounds, e.g. vitamin A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/203—Retinoic acids ; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7024—Esters of saccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161501139P | 2011-06-24 | 2011-06-24 | |
| PCT/US2012/043875 WO2012178108A1 (en) | 2011-06-24 | 2012-06-22 | Prevention and treatment of inflammatory conditions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2723347T3 true DK2723347T3 (da) | 2019-11-18 |
Family
ID=47422987
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK12803312T DK2723347T3 (da) | 2011-06-24 | 2012-06-22 | Forebyggelse og behandling af inflammationstilstande |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US9949996B2 (da) |
| EP (2) | EP2723347B1 (da) |
| JP (2) | JP6441073B2 (da) |
| KR (2) | KR102164567B1 (da) |
| CN (2) | CN103732231B (da) |
| AU (1) | AU2012272642B2 (da) |
| BR (1) | BR112013033309B1 (da) |
| CA (1) | CA2840272C (da) |
| DK (1) | DK2723347T3 (da) |
| ES (1) | ES2759584T3 (da) |
| MX (1) | MX367850B (da) |
| RU (1) | RU2678561C9 (da) |
| WO (1) | WO2012178108A1 (da) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2723347B1 (en) | 2011-06-24 | 2019-09-04 | GRI Bio, Inc. | Prevention and treatment of inflammatory conditions |
| WO2014113695A1 (en) | 2013-01-18 | 2014-07-24 | Cornell University | Methods of treating diseases associated with high fat diet and vitamin a deficiency using retinoic acid receptor agonists |
| CN106211757B (zh) * | 2014-01-17 | 2022-06-07 | 康奈尔大学 | 使用维甲酸受体激动剂治疗代谢综合征相关病况的方法 |
| US11191755B2 (en) | 2014-01-17 | 2021-12-07 | Cornell University | Compositions and methods for providing cardioprotective effects |
| MX2016010998A (es) | 2014-02-27 | 2017-03-31 | Lycera Corp | Terapia celular adoptiva que usa un agonista de receptor huérfano gamma relacionado con receptor de ácido retinoico y métodos terapéuticos relacionados. |
| CN106572663B (zh) * | 2014-03-10 | 2020-09-29 | 康奈尔大学 | 用于头颈癌的联合疗法 |
| US9896441B2 (en) | 2014-05-05 | 2018-02-20 | Lycera Corporation | Tetrahydroquinoline sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease |
| JP6523337B2 (ja) | 2014-05-05 | 2019-05-29 | リセラ・コーポレイションＬｙｃｅｒａ Ｃｏｒｐｏｒａｔｉｏｎ | ＲＯＲγのアゴニストとしての使用及び疾患治療のためのベンゼンスルホンアミド及び関連化合物 |
| KR102665487B1 (ko) * | 2014-12-09 | 2024-05-10 | 쥐알아이 바이오,아이엔씨. | 염증 질환의 예방 및 치료 |
| CA2982847A1 (en) | 2015-05-05 | 2016-11-10 | Lycera Corporation | Dihydro-2h-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of ror.gamma. and the treatment of disease |
| HK1253734A1 (zh) | 2015-06-11 | 2019-06-28 | The Regents Of The University Of Michigan | 用作RORγ激动剂和用於治疗疾病的芳基二氢-2H-苯并[B][1，4]恶嗪磺酰胺和相关化合物 |
| US11931327B2 (en) | 2017-07-04 | 2024-03-19 | Daiichi Sankyo Company, Limited | Drug for retinal degenerative disease associated with photoreceptor degeneration |
| WO2019241597A1 (en) * | 2018-06-14 | 2019-12-19 | Cornell University | Compositions and methods for providing cardioprotective effects |
| US12115140B2 (en) | 2020-07-31 | 2024-10-15 | The Trustees Of Columbia University In The City Of New York | Method of treating adenoid cystic carcinoma |
| CN113207799B (zh) * | 2021-03-19 | 2022-03-15 | 中山大学 | 一种二型糖尿病小鼠快速心衰模型的构建方法 |
| EP4401829A4 (en) * | 2021-09-15 | 2025-07-16 | Univ Cornell | COMPOSITIONS AND METHODS FOR ALLEVIATING ALCOHOLIC LIVER DISEASE |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1338627C (en) | 1985-12-04 | 1996-10-01 | Hansjorg Eibl | Pharmaceuticals based on phosphoric acid esters for use in tumor therapy, and process for their preparation |
| JP3879938B2 (ja) * | 1994-03-31 | 2007-02-14 | 日本ケミカルリサーチ株式会社 | 抗炎症剤 |
| JPH08109134A (ja) | 1994-10-11 | 1996-04-30 | Sanwa Kagaku Kenkyusho Co Ltd | 細胞変成抑制並びに臓器毒性軽減剤 |
| US6025388A (en) | 1995-04-26 | 2000-02-15 | Allergan Sales, Inc. | Method for inhibiting gene expression promoted by AP1 protein with RARβ selective retinoids and method for treatment of diseases and conditions with such retinoids |
| US5624957A (en) * | 1995-06-06 | 1997-04-29 | Bristol-Myers Squibb Company | Rary-specific retinobenzoic acid derivatives |
| FR2739557B1 (fr) | 1995-10-09 | 1997-11-14 | Cird Galderma | Utilisation d'un ligand agoniste specifique rar-gamma |
| US5965606A (en) | 1995-12-29 | 1999-10-12 | Allergan Sales, Inc. | Methods of treatment with compounds having RAR.sub.α receptor specific or selective activity |
| WO1998008546A2 (en) * | 1996-08-28 | 1998-03-05 | Institut National De La Sante Et De La Recherche Medicale | Therapeutic combinations of rar antagonists and rxr agonists and use thereof |
| SI1051159T1 (en) | 1998-01-22 | 2002-10-31 | Zentaris Ag | Solid pharmaceutical compositions containing miltefosine for oral administration in the treatment of leishmaniasis |
| JO2178B1 (en) | 1999-10-19 | 2003-04-23 | اف . هوفمان لاروش ايه جي | Treatment of invasive diseases, using selected anti-PAR materials |
| US7390795B2 (en) | 2000-12-18 | 2008-06-24 | Pentraxin Therapeutics Limited | Treatment and prevention of tissue damage |
| US7419958B2 (en) * | 2001-03-26 | 2008-09-02 | Dana-Farber Cancer Institute, Inc. | Method of attenuating reactions to skin irritants |
| JP2006514094A (ja) * | 2002-11-29 | 2006-04-27 | ゲーペーツェー バイオテック アクチェンゲゼルシャフト | Ｃ型肝炎ウイルス感染に対して有用な製剤 |
| US20050026950A1 (en) * | 2003-07-30 | 2005-02-03 | Allergan, Inc. | Methods of therapeutic treatment using retinoids to achieve consistent bioavailability |
| CN1210041C (zh) * | 2003-09-29 | 2005-07-13 | 中国医学科学院皮肤病研究所 | 治疗痤疮的复方外用药物 |
| WO2005120479A1 (en) | 2004-06-09 | 2005-12-22 | Gpc Biotech Ag | Use of selenium or a selenium salt and a retinoid acid or a retinoid in the treatment of viral hepatitis c |
| EP1940418B1 (en) | 2005-09-29 | 2011-01-19 | Torrey Pines Institute For Molecular Studies | Sulfatides for treatment of autoimmune disorders |
| US20110118197A1 (en) | 2005-09-29 | 2011-05-19 | Vipin Kumar Chaturvedi | Prevention of hepatic ischemic reperfusion injury by administration of sulfatides |
| AU2006328957C1 (en) | 2005-12-23 | 2013-01-10 | Jado Technologies Gmbh | Means and methods for the treatment and prevention of allergic diseases |
| DE102006019906A1 (de) | 2006-04-28 | 2007-10-31 | Müller-Enoch, Dieter, Prof. Dr. | Verwendung von Verbindungen der Formel A-R-X oder deren pharmazeutisch akzeptable Salze zur Herstellung einer pharmazeutischen Zubereitung |
| EP2097075A1 (fr) | 2006-11-20 | 2009-09-09 | Galderma Research & Development, S.N.C. | Utilisation d'adapalène pour moduler l'expression de cd1d ou il-10. |
| EA022322B1 (ru) * | 2009-07-16 | 2015-12-30 | Стифел Лэборетриз, Инк. | Производные тазаротена, фармацевтическая композиция, включающая их, и их применение для изготовления лекарственного средства для лечения заболеваний кожи |
| IT1403356B1 (it) | 2010-12-27 | 2013-10-17 | Sit La Precisa Spa Con Socio Unico | Dispositivo per il controllo dell'erogazione di un gas combustibile verso un bruciatore, particolarmente per apparecchi riscaldatori di acqua |
| DK2809648T3 (da) | 2011-05-26 | 2019-06-17 | Gri Bio Inc | Oxygenberigede amino- eller ammonium-holdige sulfonsyrederivater og disses medicinske anvendelse |
| EP2723347B1 (en) | 2011-06-24 | 2019-09-04 | GRI Bio, Inc. | Prevention and treatment of inflammatory conditions |
| US9005490B2 (en) | 2012-12-14 | 2015-04-14 | Delphi Technologies, Inc. | Material for solid state sintered material |
| JP2016515602A (ja) | 2013-04-08 | 2016-05-30 | アカデミッシュ メディッシュ セントラム | Ｉｂｄの治療に使用するためのミルテホシンまたはペリホシン |
| KR102665487B1 (ko) | 2014-12-09 | 2024-05-10 | 쥐알아이 바이오,아이엔씨. | 염증 질환의 예방 및 치료 |
-
2012
- 2012-06-22 EP EP12803312.3A patent/EP2723347B1/en active Active
- 2012-06-22 ES ES12803312T patent/ES2759584T3/es active Active
- 2012-06-22 EP EP19195197.9A patent/EP3616701A1/en active Pending
- 2012-06-22 KR KR1020197036256A patent/KR102164567B1/ko active Active
- 2012-06-22 CN CN201280039650.6A patent/CN103732231B/zh active Active
- 2012-06-22 KR KR1020147001610A patent/KR102055395B1/ko active Active
- 2012-06-22 CA CA2840272A patent/CA2840272C/en active Active
- 2012-06-22 DK DK12803312T patent/DK2723347T3/da active
- 2012-06-22 BR BR112013033309-0A patent/BR112013033309B1/pt active IP Right Grant
- 2012-06-22 MX MX2013015441A patent/MX367850B/es active IP Right Grant
- 2012-06-22 JP JP2014517228A patent/JP6441073B2/ja active Active
- 2012-06-22 CN CN202010113948.3A patent/CN111298120A/zh active Pending
- 2012-06-22 AU AU2012272642A patent/AU2012272642B2/en active Active
- 2012-06-22 WO PCT/US2012/043875 patent/WO2012178108A1/en not_active Ceased
- 2012-06-22 US US14/128,566 patent/US9949996B2/en active Active
- 2012-06-22 RU RU2014100056A patent/RU2678561C9/ru active
-
2017
- 2017-06-07 JP JP2017112987A patent/JP2017206523A/ja active Pending
-
2018
- 2018-03-06 US US15/913,541 patent/US10925886B2/en active Active
-
2021
- 2021-02-22 US US17/182,098 patent/US11660309B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2723347T3 (da) | Forebyggelse og behandling af inflammationstilstande | |
| DK2882441T3 (da) | Behandling af immunrelaterede og inflammatoriske sygdomme | |
| DK2882496T3 (da) | Behandling og diagnosticering af melanom | |
| DK2688557T3 (da) | Fremgangsmåder og sammensætninger til behandling af forstyrelse af opmærksomhed | |
| DK2776567T3 (da) | Sammensætninger og fremgangsmåder til behandling af cytomegalovirus. | |
| DK2691443T3 (da) | Konjugerede lipomerer og anvendelser af disse | |
| DK2898061T3 (da) | Probiotiske sammensætninger til behandlingen af fedme og fedme-relaterede tilstande | |
| DK2958588T3 (da) | Kombination af vaccination og hæmning af PD-1-reaktionsvejen | |
| DK2768321T3 (da) | Fremgangsmåder og sammensætninger til induktion af mæthed | |
| DK2846809T3 (da) | Behandling af myelosuppression | |
| DK2739293T3 (da) | Fremgangsmåder og sammensætninger til frembringelse af vaccinavirus | |
| LT2885010T (lt) | Tautopatijos gydymo būdai | |
| DK2658551T3 (da) | Behandling af erektil dysfunktion og andre indikationer | |
| DK2717941T3 (da) | Behandling af cancer | |
| PL2640375T3 (pl) | Sposób leczenia nefropatii pokontrastowej | |
| DK2785349T4 (da) | Kombinationsbehandling af cancer | |
| PL2704737T3 (pl) | Terapeutyczne kompozycje nukleaz i sposoby | |
| DK2793895T3 (da) | Fremgangsmåder og sammensætninger til reducering af kropsfedt og adipocytter | |
| DK2830654T3 (da) | Metoder og sammensætninger til behandling af inflammation | |
| DK2661274T3 (da) | Sammensætninger og fremgangsmåder med aloepolysaccharider | |
| DK2680829T3 (da) | Sammensætninger og metoder til ikke-kirurgisk behandling af ptosis | |
| IL231092A0 (en) | Treatment of rhinitis | |
| DK3292873T3 (da) | Kombination af vaccination og hæmning af PD-1-vejen | |
| DK2646452T3 (da) | Chlorering af carbohydrater og carbohydratderivater | |
| DK2854910T3 (da) | Ceramidniveauer i behandling og forebyggelse af infektioner |